US Patent

US9212204 — Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid

Method of Use · Assigned to Neuren Pharmaceuticals Ltd New Zealand · Expires 2032-01-27 · 6y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating Autism Spectrum Disorders, including Rett Syndrome, using glycyl-2-methylprolyl-glutamic acid and its analogs.

USPTO Abstract

This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental DisorderâNot Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.

Drugs covered by this patent

Daybue (TROFINETIDE) · Acadia Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3556`	—	Daybue
`U-3556`	—	Daybue
`U-3556`	—	Daybue
`U-3556`	—	Daybue

Patent Metadata

Patent number: US9212204
Jurisdiction: US
Classification: Method of Use
Expires: 2032-01-27
Drug substance claim: No
Drug product claim: No
Assignee: Neuren Pharmaceuticals Ltd New Zealand
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.